| Literature DB >> 21741595 |
Michael Heuser1, Haiyang Yun, Tobias Berg, Eric Yung, Bob Argiropoulos, Florian Kuchenbauer, Gyeongsin Park, Iyas Hamwi, Lars Palmqvist, Courteney K Lai, Malina Leung, Grace Lin, Anuhar Chaturvedi, Basant Kumar Thakur, Masayuki Iwasaki, Mikhail Bilenky, Nina Thiessen, Gordon Robertson, Martin Hirst, David Kent, Nicola K Wilson, Bertie Göttgens, Connie Eaves, Michael L Cleary, Marco Marra, Arnold Ganser, R Keith Humphries.
Abstract
Pathways defining susceptibility of normal cells to oncogenic transformation may be valuable therapeutic targets. We characterized the cell of origin and its critical pathways in MN1-induced leukemias. Common myeloid (CMP) but not granulocyte-macrophage progenitors (GMP) could be transformed by MN1. Complementation studies of CMP-signature genes in GMPs demonstrated that MN1-leukemogenicity required the MEIS1/AbdB-like HOX-protein complex. ChIP-sequencing identified common target genes of MN1 and MEIS1 and demonstrated identical binding sites for a large proportion of their chromatin targets. Transcriptional repression of MEIS1 targets in established MN1 leukemias demonstrated antileukemic activity. As MN1 relies on but cannot activate expression of MEIS1/AbdB-like HOX proteins, transcriptional activity of these genes determines cellular susceptibility to MN1-induced transformation and may represent a promising therapeutic target.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21741595 PMCID: PMC3951989 DOI: 10.1016/j.ccr.2011.06.020
Source DB: PubMed Journal: Cancer Cell ISSN: 1535-6108 Impact factor: 31.743